Atara Biotherapeutics Exercises Exclusive License to T-Cell

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Atara Biotherapeutics Exercises Exclusive License to T-Cell Technology From Memorial Sloan Kettering Cancer Center

SOUTH SAN FRANCISCO, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ) today announced that it has exercised its exclusive option with Memorial Sloan Kettering Cancer Center (MSK) to license certain clinical stage, allogeneic T-cell therapies for the treatment of cancers and persistent viral infections. In connection with the exercise of the option, the Atara Bio license agreement with MSK grants Atara Bio exclusive worldwide rights to the following three allogeneic T-cell therapies:

  • T-cells activated against Epstein Barr Virus, or EBV (Phase 2);
  • T-cells activated against Cytomegalovirus, or CMV (Phase 2); and
  • T-cells activated against Wilms Tumor 1, or WT1 (Phase 1)

These three programs share a common technology, under which third-party donor-derived whole blood is collected and enriched for T lymphocytes, or T-cells. The T-cells are then exposed to certain antigens, and the resulting activated T-cells are characterized and stored for future therapeutic use. Using a proprietary algorithm, patients are treated with a partially human leukocyte antigen, or HLA, matched cell line, providing an "off-the-shelf," allogeneic, cellular therapeutic option for patients. These T-cell products are intended to work by targeting the abnormal cells expressing the applicable target antigen and killing them.

Atara Bio announced earlier this year that its collaborating investigator at MSK received breakthrough therapy designation from the U.S. Food and Drug Administration for its cytotoxic T lymphocytes (CTL) activated against Epstein-Barr Virus (EBV-CTL) in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD).

Clinical data have been presented as follows:

  • EBV-CTL in the treatment of patients with EBV-LPD after solid organ transplantation at the 2015 American Society of Clinical Oncology Annual Meeting.
  • EBV-CTL in the treatment of  patients with EBV-LPD after allogeneic hematopoietic cell transplantation (HCT) at a Clinical Trial Plenary Session at American Association for Cancer Research Annual Meeting 2015
  • CMV-CTL in the treatment of patients with anti-viral resistant CMV after HCT including viremia only and CMV disease at the American Society of Hematology Annual Meeting 2014.

"Licensing these programs more than doubles the clinical stage programs active at Atara Bio and provides a potential platform technology that can be directed at other targets," said Isaac Ciechanover, MD, Chief Executive Officer and President of Atara Bio. "Our T-cell programs use third party donor cells, and, if approved by regulatory authorities, will be available as "off-the-shelf" therapies for patients in need."

Richard O'Reilly, MD, Chair of the Department of Pediatrics and Chief of the Pediatric Bone Marrow Transplant Service at MSK, notes that "We are delighted that Atara will continue to develop our existing T-cell technologies that have shown promising clinical benefit in patients. We also look forward to expanding the platform to treat patients with other types of cancer through our sponsored research efforts with Atara." Dr. O'Reilly will join Atara Bio's Scientific Advisory Board.

In connection with the exercise of the option and entry into the exclusive license agreement, MSK received an upfront license fee and will be eligible to receive additional payments based on the achievement of certain development, regulatory and sales-related milestones, as well as royalty payments. Atara Bio and MSK have agreed to collaborate on further research to develop additional cellular therapies, which may include T-cell therapies targeted against other antigens and/or chimeric antigen receptor-modified T-cells, known as CAR-T.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara Bio's programs include molecularly-targeted product candidates and T-cell product candidates. The molecularly-targeted product candidates include PINTA 745, STM 434 and ATA 842, targeting myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications.  T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL.

Forward-Looking Statements

This press release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Because such statements deal with future events and are based on Atara Bio's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Bio could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the clinical development of product candidates and Atara Bio's collaboration with MSK. These forward-looking statements are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Atara Bio's quarterly report on Form 10-Q for the quarter ended March 31, 2015 and subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, Atara Bio disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

INVESTOR & MEDIA CONTACT: Tina Gullotta, Atara Biotherapeutics, Inc. 650-741-1613

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 65

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 116

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
NCPDP Elevates J.W. Hill to President & COO Role

Updated Category News Views 46

Plotting the Course for NCPDP's Future Today's shakeup at the NCPDP has got the sector's ears perked. For those who don't speak in acronym soup all day—NCPDP stands for National Council for Prescription Drug Programs. They're the brains behind many crucial healthcare standards, improving information flow around meds, supplies, and services. Now, they're taking bold...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 170

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 68

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 210

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
LA Auto Show 2026: Thrills, Games, and Cars Galore

Updated Category News Views 53

A Family Day Like No Other at the LA Auto Show Kicking into gear this November, the 2026 Los Angeles Auto Show puts the pedal to the metal for families seeking a full day of fun without breaking the bank. We're talking about 10 solid days where auto-mania meshes with interactive experiences, all nestled in the Los Angeles Convention Center. Whether you're a gearhead or a...

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 45

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 100

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading

Top 5 Most Recently Viewed Articles

Patriot Rail Company Celebrated as a Top Workplace in 2025

Updated Category News Views 218

Patriot Rail Company Achieves Top Workplace Recognition Patriot Rail Company, a leading provider of short line and regional freight rail services, has proudly been recognized as one of the Top Workplaces for 2025 by USA TODAY. This prestigious award celebrates companies that prioritize their employees, ensuring a culture that is rich in support and engagement....

Continue Reading
Transform Your Holiday Spirit with Unique DIY Christmas Ornaments

Updated Category News Views 173

Discover the Joy of DIY Christmas Tree Ornaments As the holiday season approaches, families often seek special ways to celebrate and remember the joy of Christmas. One delightful approach is creating DIY Christmas tree ornaments. Handmade ornaments not only add warmth and creativity to your holiday decor, but they also give a personal touch that store-bought items simply...

Continue Reading
Understanding SkyWest Inc's Price to Earnings Ratio

Updated Category News Views 111

SkyWest Inc's Current Market Performance SkyWest Inc. (NASDAQ: SKYW) is currently seeing its share price at $102.58, marking a notable increase of 1.95% in the recent trading session. However, when looking at the broader picture, the stock has experienced a decline of 17.54% over the last month, while over the last year, the price has surprisingly surged by 20.94%. This...

Continue Reading
Luxury Brands Thrive Amid Positive Sales Trends

Updated Category News Views 366

Luxury Goods Market Experience Significant Upturn Today, shares in prestigious luxury goods companies witnessed a remarkable surge during European trading sessions. This surge follows a compelling end-of-year sales report from Richemont, renowned for its luxurious Cartier brand. The impressive sales performance has ignited optimism about a broader recovery within the...

Continue Reading
Actabl Welcomes Joseph Benjamin as New Technology Leader

Updated Category News Views 240

Actabl Welcomes Joseph Benjamin as New Technology Leader Actabl, a prominent software provider in the hospitality sector, has won a significant addition to its team with the appointment of Joseph Benjamin as the Chief Technology Officer (CTO). Joseph’s presence marks a pivotal moment for Actabl as it enhances its global technology strategies aimed at driving innovation...

Continue Reading